We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
1. Cancer treatment paradigms
- Prof. Sharon Marsh
-
2. Clinical research and care in the era of ‘N-of-1’ precision cancer medicine
- Prof. Maurie Markman
- Clinical Pharmacology Considerations in Cancer Treatment
-
3. Overview of clinical pharmacology in cancer 1
- Prof. Jill Kolesar
-
4. Overview of clinical pharmacology in cancer 2
- Prof. Jill Kolesar
-
5. Drug metabolizing enzymes in cancer therapeutics
- Prof. Bhagwat Prasad
- Treatment paradigms
-
6. Key considerations for cancer pharmacotherapy 1
- Prof. Christine M. Walko
-
7. Key considerations for cancer pharmacotherapy 2
- Prof. Christine M. Walko
-
8. A systems approach to implementation of personalized cancer therapy
- Prof. Gordon B. Mills
-
9. CML: genetic paradigm of targeted therapy 1
- Prof. Michael W. Deininger
-
10. CML: genetic paradigm of targeted therapy 2
- Prof. Michael W. Deininger
-
11. Novel treatment options in lymphoma and leukemia 1
- Prof. Nishitha M. Reddy
-
12. Novel treatment options in lymphoma and leukemia 2
- Prof. Nishitha M. Reddy
-
13. Novel treatments for GI malignancies
- Prof. Bert H. O'Neil
Printable Handouts
Navigable Slide Index
- Introduction
- Lenalidomide: mechanisms of action
- Rituximab + lenalidomide improves remission rate
- Lenalidomide and rituximab in iNHL
- Lenalidomide in mantle cell lymphoma (MCL)
- Lenalidomide vs. investigator's choice
- MCL front line: lenalidomide + rituximab
- Targeting the BTK pathway
- Targeting BTK with ibrutinib in MCL
- MCL relapsed/refractory: BTK inhibitor + rituximab
- Ibrutinib vs. ofatumumab in previously treated CLL
- Response to therapy & progression free survival
- RESONATE-2: ibrutinib as initial therapy for CLL
- Improvement in PFS and OS with ibrutinib
- PI3K inhibition as a target in cancer
- PI3Kd inhibition by idelalisib
- Idelalisib and rituximab study
- Idelalisib and rituximab study (results)
- Venetoclax: BCL2 inhibitor in CLL
- Venetoclax: duration of response
- Anti-CCR4 monoclonal antibody for ATL
- Novel agents in leukemia
- CPX-351
- Vosaroxin
- FLT3 inhibitors
- IDH1 and IDH2 inhibitors
Topics Covered
- Immunomodulatory agents (immunotherapy)
- Emerging treatments in leukemia
- Future therapeutic options in lymphoma and leukemia
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Reddy, N.M. (2017, May 29). Novel treatment options in lymphoma and leukemia 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/WRYV5012.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Nishitha M. Reddy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Novel treatment options in lymphoma and leukemia 2
Published on May 29, 2017
38 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:04
So we'll now be moving on
to another class of drugs
called immunomodulatory agents
and a few examples
in these class of drugs
are lenalidomide and pomalidomide.
So these drugs have
a unique class of action
and several pathways
have been recognized
as being involved that are targeted
by these novel group of agents.
Several investigators
have reported antiproliferative
and pro-apoptotic effects
of immunomodulatory agents
on tumor cells in vitro.
An important effect
of the immunomodulatory agents
is its ability to modulate production
of various cytokines
in the tumor microenvironment.
Lenalidomide is reported
to down regulate
key pro-survival cytokines
such as tumor necrosis factor,
the TNF alpha
and interleukin-6, interleukin-8,
and Vascular Endocrinal Growth Factor
or the VEGF.
Cytokines that enrich
the malignant microenvironment
favoring tumor cell survival
and proliferation
and resistance to therapy as well.
Lenalidomide may also affect
other components
of the tumor microenvironment
including
the immune cellular compartment.
The preclinical observations
demonstrate its activity
of immune effector cells
such as the T-cells and the NK cells,
stimulating T-cell proliferation
and increased production of IL-2
and interferon gamma
through T-cell receptor activation.
Also activation
and proliferation of NK cells
has been reported with lenalidomide.
So there is no one specific mechanism
of action of these agents
and with its varied mechanism
of actions,
it is unclear as to
if one particular pathway
is more active,
suggesting its better treatment
in either lymphomas or multiple myeloma
where it has received its approval
for multiple myeloma.
While lenalidomide is approved
in combination with the steroids
or other monoclonal antibodies
in multiple myeloma,
in lymphoma,
it's currently under investigation,
specifically in indolent lymphomas.
Lenalidomide is approved, however,
for mantle cell lymphoma
and in the next few slides
we will be discussing various studies
involving lenalidomide.